19.5: Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).

Epinephrine

• Indication: Epinephrine is the first-line drug for all cardiac arrest rhythms.
• Mechanism of Action: Epinephrine increases coronary and cerebral perfusion by stimulating alpha-adrenergic receptors, leading to vasoconstriction. Additionally, it stimulates beta-1 adrenergic receptors, enhancing myocardial contractility and heart rate. These effects improve perfusion pressure and increase the chances of successful resuscitation during CPR.
• Administration: Administer 1 mg IV/IO every 3–5 minutes during CPR.

Amiodarone

• Indication: Amiodarone is used for shock-refractory ventricular fibrillation or pulseless ventricular tachycardia, especially after defibrillation and epinephrine.
• Mechanism of Action: Amiodarone primarily blocks potassium channels, prolonging the action potential and refractory period. It helps stabilize the cardiac membrane. Additionally, it affects sodium and calcium channels, contributing to its antiarrhythmic effects.
• Administration: Administer an initial dose of 300 mg IV/IO bolus. If required, a second dose of 150 mg IV/IO may be given if needed.

Lidocaine

• Indication: Lidocaine is an alternative to amiodarone for refractory ventricular fibrillation or pulseless ventricular tachycardia, typically used as a second-line treatment.
• Mechanism of Action: Lidocaine blocks sodium channels, reducing automaticity and conduction velocity and suppressing ventricular arrhythmias.
• Administration: Administer an initial dose of 1–1.5 mg/kg IV/IO. Subsequent doses of 0.5–0.75 mg/kg IV/IO may be administered as needed.

ACLS algorithms for different arrest scenarios

1. Pulseless Ventricular Tachycardia/Ventricular Fibrillation (VT/VF): Start with immediate defibrillation. If the patient remains in VT/VF, administer epinephrine every 3–5 minutes. Antiarrhythmic drugs like amiodarone or lidocaine should be administered after the second shock.
2. Asystole or Pulseless Electrical Activity (PEA): Administer epinephrine every 3–5 minutes while continuing high-quality CPR throughout the resuscitation effort.

Effective team dynamics

Successful ACLS outcomes depend heavily on effective team dynamics. The team leader must ensure that roles are clearly assigned, communication is consistent, and interventions are regularly reassessed for effectiveness. All team members should be thoroughly familiar with ACLS protocols, including the correct dosages, routes of administration, and timing of drug interventions.

Post-cardiac arrest care

Once the ROSC or Return of Spontaneous Circulation is accomplished, the focus shifts to maintaining hemodynamic stability and preventing secondary complications. It is done through pharmacologic support and neuroprotective strategies, including the use of vasopressors and chronotropic agents.

1. Vasopressors:
   • Norepinephrine: This vasopressor is commonly used to treat hypotension after ROSC due to its potent vasoconstrictive effects, which increase blood pressure without significantly increasing heart rate. It is typically administered as a continuous IV infusion at 0.1–0.5 mcg/kg/min, preferably through a central line.
   • Dopamine: Dopamine may be considered in cases of persistent hypotension, especially when bradycardia is present. It supports both blood pressure and cardiac contractility. Dopamine is administered as an IV infusion at 5–10 mcg/kg/min.
2. Chronotropic Agents:
   • Atropine: This drug is indicated for symptomatic bradycardia, particularly when associated with hypotension and poor perfusion. It increases heart rate by inhibiting parasympathetic influences. Administer atropine 0.5 mg IV push, repeating every 3–5 minutes as needed, up to a total dose of 3 mg.
3. Targeted Temperature Management (TTM): TTM reduces the risk of neurological injury. Current guidelines recommend maintaining the patient's core temperature between 32–36°C for at least 24 hours, followed by vigilant fever prevention to minimize further neurological damage.

Summary

Pharmacologic management during Advanced Cardiovascular Life Support (ACLS) adheres to established guidelines to maximize favorable outcomes in cardiac arrest scenarios. Essential drugs, such as epinephrine, amiodarone, and lidocaine, are administered based on specific algorithms tailored to the patient's cardiac arrest rhythm. Effective team coordination, clear communication, and post-cardiac arrest care—especially using vasopressors and Targeted Temperature Management (TTM)—are essential to improving survival rates and minimizing neurological injury.